New York-based drug major Pfizer is to acquire King Pharmaceuticals in a $3.6bn deal.
The deal will strengthen the company’s portfolio before the expiry of key patents next year, including its key cholesterol fighter Lipitor, and provide a bigger share in the prescription pain relief market.
Go deeper with GlobalData
Pfizer will fund the deal, priced at a 40% premium of King’s closing price on Monday, entirely through existing cash.
The company expects to make savings of more than $200m from the transaction.
Pfizer will use existing and developmental King’s medications to expand its pain treatment portfolio, which already includes Lyrica and Celebrex.
Pfizer acquired Wyeth for $67bn earlier this year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
